Stellantis warns of $2.68B loss in first half of 2025
Now, experts tell DailyMail.com that consumers should expect to see a lineup of rumbling gas-burners at US dealerships to boost those sales. 'Brand portfolio decisions made under the prior leadership missed the core needs of existing Ram, Dodge, and Jeep customers,' Rella Suskin, an analyst at MorningStar, said.
'This has left wide gaps in these brands' offering relative to where the market demand lies.' The first gas-powered shoe to drop was Ram's decision to revive the Hemi V8 version of its full-size pickup truck.
Last year, the truckmaker killed the grumbly 5.7-liter engine for a more efficient, higher-powered V6 engine. But customers balked at the decision to kill the gas-guzzler, forcing the truck's top boss to apologize in a new ad campaign. 'We own it. We got it wrong. And we're fixing it,' Tim Kuniskis, the CEO of the Ram brand, said in its latest commercial, speaking over the thunderous growl of the truck's iconic V8 cylinders.
'You hear that? That's our HEMI. And it's saying, "We're back."' Suskin said the shift back to rumbling tailpipes will extend to other brands, too. She pointed out that Jeep is bringing back the mid-sized Jeep Cherokee this year, plugging the company back into the best-selling segment in American carmaking.
'For Dodge, the company had focused on a new electric version model; however, this does not speak to the core customer,' she added. 'Stellantis will look to bring back a car to appease the core customer.' The about-face comes as Stellantis faces a financial crisis that's forcing the dramatic strategy shift.
The company's staggering billion-dollar first-half loss was revealed ahead of a scheduled July 29 earnings release. The financial meltdown isn't surprising. Former CEO Carlos Tavares abruptly quit in December with two years left on his contract, leaving replacement Antonio Filosa a gargantuan clean-up task.
Meanwhile, Trump's tariffs are hammering the company hard. Stellantis has already paid $350 million in tariffs this year and expects the bill to hit $1.5 billion by December. US shipments have cratered 25 percent. But here's the kicker for car buyers: prices at dealerships are expected to jump this year, Suskin said.
Dodge currently has 118 days worth of unsold cars sitting on lots — way above the industry average of 82 days. That massive inventory glut, combined with pre-tariff vehicles still being sold off, has kept prices artificially low.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
3 minutes ago
- The Independent
Weight-loss jab Wegovy sees another prescription boost after ban on copycats
Novo Nordisk's weight loss drug, Wegovy, is experiencing a surge in new prescriptions following a US ban on its copycat versions, though analysts caution that more substantial growth is needed to reassure investors. Since the US Food and Drug Administration (FDA) implemented a ban on 'compounded' versions of Wegovy on 22 May, new prescriptions for the drug have risen by approximately 33 per cent. This culminated in 181,200 new prescriptions in the week ending 18 July, according to IQVIA data shared with Reuters by industry analysts. The overall increase in Wegovy prescriptions is also narrowing the market lead held by Eli Lilly and Co's rival drug, Zepbound. While Zepbound prescriptions outpaced Wegovy by nearly 175,000 in the US during the week ending 23 May, this gap had reduced to around 133,000 by 18 July. Early signs of a shift come at a critical juncture for Novo. After Wegovy's initial stunning success, investor confidence was rattled when Zepbound and compounders started to slow the drug's growth. And then in May, the Danish company cut its full-year sales and earnings forecasts and announced the surprise exit of Chief Executive Lars Fruergaard Jorgensen, citing market challenges and a stock price nearly 60% below its 2024 peak. Jorgensen said at the time he expected the FDA compounding ban to lift sales in the second half of this year. Investors are keen to hear whether that is still likely when the company reports quarterly earnings on August 6. That leaves the drugmaker in what Barclays analyst Emily Field called a "show me" phase - no longer buoyed by optimism about a turnaround but under pressure to deliver. She has an "overweight" rating on Novo's shares. "We thought this trajectory change (in new prescriptions) would get the shares moving, but not so far," Berenberg analyst Kerry Holford told Reuters. "I suspect investors are now waiting for the (second quarter) update - will they/won't they trim guidance range? I think they will trim the top." Berenberg has a "hold" rating on Novo. Novo did not respond to a request for comment. Investors and analysts note that the IQVIA prescription data is incomplete, because it does not capture sales of Wegovy through the company's direct-to-consumer platform, NovoCare, launched in March. They estimate the channel is still a small slice of overall Wegovy volume. "We would hope to see strong growth from the NovoCare channel but are cognizant that this may come at initially lower prices" due to discount offers, said Marcus Morris-Eyton, a portfolio manager at Alliance Bernstein, whose fund holds Novo shares. "Sentiment towards Novo Nordisk is currently exceptionally weak, but given low expectations, the low valuation and hopefully accelerating prescription data in (the second half of 2025) we believe the market is underestimating Novo's long term growth potential," he said. Booming sales of Wegovy catapulted Novo to become Europe's most valuable listed company, peaking in June 2024 at about 615 billion euros, after the weekly injection became the first highly-effective obesity treatment approved in the U.S. in 2021. But supply disruptions and gaps in health insurance coverage for Wegovy helped fuel the market for cheaper compounded - or copycat - versions, which are allowed under U.S. law when drugs are in shortage. Investor sentiment on Novo soured after the company lost ground to U.S. rival Eli Lilly, which launched Zepbound in late 2023. Capturing more of the patients who had turned to compounded drugs is key to meeting targets. The FDA determined that Wegovy was no longer in shortage in February, leading to the ban on compounded versions. Novo has rolled out new tactics to bring patients back, including a limited-time discount for one month's supply, and secured better coverage from insurer CVS Health. Analysts at Berenberg and UBS are sceptical these moves will provide enough momentum and expect that Novo will reduce or narrow its full-year guidance ranges, according to research notes. TD Cowen said the outcome was hard to predict due to limited visibility on NovoCare. Bank of America and Guggenheim said they did not expect another guidance cut and Barclays said it was unlikely. ($1 = 0.8513 euros)
BBC News
4 minutes ago
- BBC News
US-EU deal winners and losers
The US and EU have struck what is being billed as the largest trade deal in history, after talks in actually resembles the framework for an agreement rather than a full trade deal, with details still the headline figures announced by President Donald Trump and EU chief Ursula von der Leyen do offer clues about which sectors and groups could be hit hardest or have most to reaction live Trump - winner After promising new trade deals with dozens of countries, Trump has just landed the biggest of them looks to most commentators that the EU has given up more, with instant analysis by Capital Economics suggesting a 0.5% knock to will also be tens of billions of dollars pouring into US coffers in import the glowing headlines for Trump may not last long if a slew of economic data due later this week show that his radical reshaping of the US economy is on inflation, jobs, growth and consumer confidence will give a clearer picture on whether Trump's tariffs are delivering pain or gain. US consumers - loser Ordinary Americans are already aggrieved at the increased cost of living and this deal could add to the burden by hiking prices on EU not as steep as it could have been, the hurdle represented by a 15% tariff rate is still significant, and it is far more pronounced than the obstacles that existed before Trump returned to are taxes charged on goods bought from other countries. Typically, they are a percentage of a product's value. So, a 15% tariff means that a $100 product imported to the US from the EU will have a $15 dollar tax added on top - taking the total cost to the importer to $ who bring foreign goods into the US have to pay the tax to the government, and they often pass some or all of the extra cost on to customers. Markets - winner Stock markets in Asia and Europe rose on Monday after news emerged of the deal the framework, the US will levy a 15% tariff on goods imported from the EU. While this rate is significant, it is less than what it could have been and at least offers certainty for agreement is "clearly market-friendly, and should put further upside potential into the euro", Chris Weston at Pepperstone, an Australian broker, told AFP. European solidarity - loser The deal will need to be signed off by all 27 members of the EU, each of which have differing interests and levels of reliance on the export of goods to the some members have given the agreement a cautious welcome, others have been critical - hinting at divisions within the bloc, which is also trying to respond to other crises such as the ongoing war in Ukraine.A big Trump win but not total defeat for BrusselsFrench Prime Minister Francois Bayrou commented: "It is a dark day when an alliance of free peoples, brought together to affirm their common values and to defend their common interests, resigns itself to submission."He was joined by at least two other French government ministers as well as Viktor Orban, the Hungarian leader, who said that Trump "ate von der Leyen for breakfast". Carmakers in Germany - loser The tariff faced by importers bringing EU cars to the US has been nearly halved, from the rate of 27.5% that was imposed by Trump in April to a new rate of 15%.Cars are one of the EU's top exports to the US. And as the largest manufacturer of cars in the EU - thanks to VW, Mercedes and BMW - Germany will have been watching leader, Friedrich Merz, has welcomed the new pact, while admitting that he would have welcomed a "further easing of transatlantic trade".That downbeat sentiment was echoed by the German carmaking trade body, the VDA, which warned that even a rate of 15% would "cost the German automotive industry billions annually". Carmakers in the US - winner Trump is trying to boost US vehicle production. American carmakers received a boost when they learned that the EU was dropping its own tariff on US-made cars from 10% to 2.5%. Theoretically that could result in more American cars being bought in could be good for US sales overseas, but the pact is not all good news when it comes to domestic sales. That is down to the complex way that American cars are put of them are actually assembled abroad - in Canada and Mexico - and Trump subjects them to a tariff of 25% when they are brought into the US. That compares with a lower tariff rate of 15% on EU vehicles. So US car makers may now fear being undercut by European manufacturers. EU pharmaceuticals - loser There is confusion around the tariff rate that will be levied on European-made drugs being bought in the US. The EU wants drugs to be subject to the lowest rate possible, to benefit said pharmaceuticals were not covered by the deal announced on Sunday, under which the rate on a number of products was lowered to 15%. But von der Leyen said they were included, and a White House source confirmed the same to the scenario will represent disappointment for European pharma, which initially hoped for a total tariffs exemption. The industry currently enjoys high exposure to the US marketplace thanks to products like Ozempic, a star type-2 diabetes drug made in has been highlighted in Ireland, where opposition parties have pointed out the importance of the industry and criticised the damaging effect of 'not celebrating' Trump's EU deal US energy - winner Trump said the EU will purchase $750bn (£558bn, €638bn) in US energy, in addition to increasing overall investment in the US by $600bn."We will replace Russian gas and oil with significant purchases of US LNG [liquified natural gas], oil and nuclear fuels," said Von der will deepen links between European energy security and the US at a time when it has been pivoting away from importing Russian gas since its full-scale invasion of Ukraine. Aviation industry in EU and US - winner Von der Leyen said that some "strategic products" will not attract any tariffs, including aircraft and plane parts, certain chemicals and some agricultural means firms making components for aeroplanes will have friction-free trade between the huge trading added that the EU still hoped to get more "zero-for-zero" agreements, notably for wines and spirits, in the coming days.
BreakingNews.ie
4 minutes ago
- BreakingNews.ie
Tariff of 15% ‘challenging' but avoids a trade war
A tariff rate of 15 per cent is 'challenging' but avoids a rate of 30 per cent – which would have 'closed the market' in the US, The Minister for Enterprise has said. Peter Burke said that the EU-US deal avoids both a trade war and EU counter-measures, which would have had an effect on the north-south economy. Advertisement He said 'the devil is in the detail' of the trade agreement finalised on Sunday by Donald Trump and European Commission president Ursula von der Leyen in Scotland. 'We had a lot of modelling carried out on the various different options, and some were very perverse, that would have closed the market if you had over a 30 per cent tariff with a stacking mechanism,' Mr Burke told RTÉ Radio. 'The key thing is that there will be a number of carve outs. Obviously, aviation has been cited as zero-for-zero, but also in relation to agrifoods and potentially spirits.' The bloc is set to face 15 per cent tariffs on most of its goods including cars, semiconductors and pharmaceuticals entering the US and 'zero for zero' tariffs on a number of products including aircraft, some agricultural goods and certain chemicals – as well as EU purchases of US energy worth 750 billion dollars (€643 billion) over three years. Advertisement Mr Burke said it was his understanding that the 15 per cent tariff on the pharmaceutical sector would be a maximum rate. He added: 'I think the president of the Commission has been very clear that 15 per cent will be a ceiling.' It is still unclear from the deal, agreed five days before Mr Trump's threat of a 30 per cent tariff would have come into effect, will mean Ireland will need to invest in US energy, he added. 'This all has to be worked out yet, as you can appreciate, I'm only hearing this for the first time last night, and we have nothing on paper.' Advertisement Ireland's premier Micheal Martin and deputy premier Simon Harris welcomed the agreement struck on Sunday, saying that while Ireland 'regrets' the baseline tariff of 15 per cent, it welcomed the certainty for businesses. Mr Harris said further detail was needed around how tariffs would affect sectors including pharmaceuticals. Ireland remains vulnerable to a slow down in trade with the US economy, due to exports of products such as alcohol, dairy and beef. The Government has also expressed concern at how tariffs could affect pharma multinationals based in Ireland, which employs about 45,000 people in Ireland, as Mr Trump had signalled he intended to target that industry. Advertisement In addition, 65 per cent of all aircraft are leased through Ireland globally. Last week, Minister for Finance, Paschal Dohonoe said the Government would spend €9.4 billion euro on its budget in October, based on a zero-tariff scenario for next year. He and Minister for Public Expenditure, Jack Chambers said these estimates would need to be revised if there was a shock to the Irish economy. Mr Burke said it was not naive to base the government's economic scenario on a zero-for-zero trade agreement with the US. Advertisement 'No it wasn't because we didn't know what we were to be faced with,' he said on Monday. 'We do need to find out what happens in other areas, because this is very complex. 'It depends what happens with China, that's a very significant market that a deal hasn't happened yet. Ireland Hospital overcrowding: Over 450 patients on trolle... Read More 'It really impacts what happens with our exporters here in Ireland as well, because so much product is in danger of being redirected into EU market. 'We also don't know what separate carve outs are going to emerge for the different sectors that are so vulnerable from an Irish perspective. 'Until we get flesh on the bones and all those areas over the coming weeks, we'll be in a better position then to really put forward what budgetary parameters (we) will end up with.'
